Anders Lilja
Healthcare
NSF Bioensaios
Norway
Biography
Dr. Anders Lilja is VP Technical Development at Hookipa. He is responsible for further developing Hookipa’s groundbreaking science through the development of promising product candidates – from the initial research to manufacturing of the final drug. While at Hookipa, he led the preclinical characterization and manufacturing of our cytomegalovirus vaccine candidate HB-101. Prior to joining Hookipa, he was a Research Investigator and Associate Research Project Leader at Novartis Vaccines. Dr. Lilja holds an MSc in chemical engineering from Chalmers University of Technology, Sweden, a PhD in biochemistry from University of Maryland, and did postdoctoral training in molecular virology at Princeton University. He has co-authored several publications characterizing key cytomegalovirus vaccine antigens.
Research Interest
Nutrition
